These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4043378)

  • 1. Partial protection by CDP-choline against kainic acid-induced lesion in the rat caudate nucleus.
    Porceddu ML; Concas A
    Farmaco Sci; 1985 Aug; 40(8):617-22. PubMed ID: 4043378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of hypoxia and cytidine (5') diphosphocholine on the concentrations of dopamine, norepinephrine and metabolites in rat hypothalamus and striatum.
    Saligaut C; Daoust M; Moore N; Boismare F
    Arch Int Pharmacodyn Ther; 1987 Jan; 285(1):25-33. PubMed ID: 3579424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrastriatal kainic acid: acute effects on electrophysiological and biochemical measures of nigrostriatal dopaminergic activity.
    Braszko JJ; Bannon MJ; Bunney BS; Roth RH
    J Pharmacol Exp Ther; 1981 Feb; 216(2):289-93. PubMed ID: 6257886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine.
    Saligaut C; Daoust M; Chadelaud M; Moore N; Chretien P; Boismare F
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):5-8. PubMed ID: 3990445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CDP-choline on striatal dopamine level and behavior in rats.
    Shibuya M; Kageyama N; Taniguchi T; Hidaka H; Fujiwara M
    Jpn J Pharmacol; 1981 Feb; 31(1):47-52. PubMed ID: 7253343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bromocriptine on 3H-spiroperidol binding sites in rat striatum. Evidence for actions of dopamine receptors not linked to adenylate cyclase.
    Schwarcz R; Fuxe K; Agnati LF; Gustafsson JA
    Life Sci; 1978 Aug; 23(5):465-9. PubMed ID: 692269
    [No Abstract]   [Full Text] [Related]  

  • 8. The site of dopamine formation in rat striatum after L-dopa administration.
    Hefti F; Melamed E; Wurtman RJ
    J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral CDP-choline on acrylamide-induced lesion.
    Agut J; Font E; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1983; 33(7A):1029-33. PubMed ID: 6684458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acute and chronic ethanol on dopamine synthesis in the caudate nucleus, substantia nigra and frontal cortex.
    Fadda F; Argiolas A; Melis MR; Serra G
    Boll Soc Ital Biol Sper; 1980 Dec; 56(24):2553-8. PubMed ID: 7470302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine.
    Agut J; Coviella IL; Wurtman RJ
    Neuropharmacology; 1984 Dec; 23(12A):1403-6. PubMed ID: 6543245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible decrease in dopaminergic 3H-agonist binding after 6-hydroxydopamine and irreversible decrease after kainic acid.
    Schweitzer BI; Bacopoulos NG
    Life Sci; 1983 Jan; 32(5):531-40. PubMed ID: 6296593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture.
    Radad K; Gille G; Xiaojing J; Durany N; Rausch WD
    Int J Neurosci; 2007 Jul; 117(7):985-98. PubMed ID: 17613109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of supidimide on brain neurotransmitter systems of rats and mice.
    Hennies HH; Günzler WA; Flohé L
    Arzneimittelforschung; 1984; 34(11):1471-80. PubMed ID: 6084511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of cytidine-diphosphate choline (CDP-choline) on brain lipid changes during aging.
    De Medio GE; Trovarelli G; Piccinin GL; Porcellati G
    J Neurosci Res; 1984; 11(1):49-58. PubMed ID: 6708133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline.
    Agut J; Font E; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1983; 33(7A):1048-50. PubMed ID: 6684464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of chronic haloperidol on caudate 3H-spiroperidol binding in lesioned rats.
    Rosenblatt JE; Shore D; Neckers LM; Perlow MJ; Freed WJ; Wyatt RJ
    Eur J Pharmacol; 1979 Dec; 60(4):387-8. PubMed ID: 93551
    [No Abstract]   [Full Text] [Related]  

  • 19. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease.
    Cubells JM; Hernando C
    Clin Ther; 1988; 10(6):664-71. PubMed ID: 3064905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.